News

The trial will evaluate the efficacy and safety of itacitinib, Incyte’s novel, potent, and selective JAK1 inhibitor, in combination with corticosteroids compared to placebo plus corticosteroids in patients

LUSDUNA Nexvue is being developed by Merck with funding from Samsung Bioepis. With the tentative approval, LUSDUNA Nexvue has met all required regulatory standards for follow-on biologics of

The approval allows to market Kyntheum in all 28 European Union (EU) member countries, as well as Iceland, Liechtenstein and Norway. Kyntheum is a new biologic medicine developed

Top line data from this trial, being conducted in Italy, Israel, Greece and Turkey, is expected in Q4 2018. The primary objective of this multi-centre, multi-country and dose-ranging

These are the first data to demonstrate the potential to treat the underlying cause of CF in these patients, who have a severe and difficult-to-treat type of the

Dharmacon, which manufactures RNAi products, has a portfolio of gene editing products, particularly in CRISPR reagents and arrayed libraries. It had generated revenues of $36.7m in 2016 with an EBITDA of $5.4m.

Raxibacumab is a fully human monoclonal antibody, which secured approval from the US Food and Drug Administration (FDA) for the treatment and prophylaxis of inhalational anthrax due to

One of the important non-motor features of Parkinson’s disease is often the early presentation of severe and disabling impairment of gastrointestinal function. Parkinson’s disease is characterised by the

The two companies have also entered into a license agreement which gives the global exclusive rights of BioMarin's DMD patent estate to Sarepta Therapeutics for $35m. Sarepta will